Celea Therapeutics received $180 million in financing to develop deupirfenidone (LYT-100), an investigational therapy that the company says has the potential to serve as a new standard of care for people with idiopathic pulmonary fibrosis (IPF). The funding will support the planned launch of SURPASS-IPF (NCT07284602), a…
Discussion
I feel like I’m in a long scene from the classic movie “The Neverending Story,” and the dark force is shingles. As I write this, I’m still hospitalized while my care team works to address the complications of this infection in a post-transplant patient. I’m determined to write this…
Discussion
Problems in a cell death process called ferroptosis may contribute to the formation of scar tissue in the lungs in idiopathic pulmonary fibrosis (IPF), a study suggests. In ferroptosis, which is an iron-dependent process, reactive oxygen molecules damage cell membranes, leading to cell death. In the study, the researchers described…
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
